4SC AG
4SC Announces First Patient Treated in a Phase II Hodgkin's Lymphoma Study with HDAC Inhibitor Resminostat 4SC-201
Published in Oncology Business Week, January 31st, 2010
In this open-label, single-arm, Simon-design two-stage Phase II study entitled 'SAPHIRE', resminostat will be given orally at a dose of 600mg daily for five consecutive days, followed by a nine day treatment free period ('5+9' dosing schedule). In the main phase of the trial, patients will receive treatment for six cycles (12 weeks)....
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Oncology Business Week
More Articles from Oncology Business Week
- 2Insure4Less.com
2Insure4Less.com's Free Online Comparison Service and iPhone App Help Consumers Start the New Year Right with Strategic Insurance Shopping - A.P. Pharma, Inc.
A.P. Pharma Receives $2.5 Million Milestone Payment - Aasld
AASLD Applauds Landmark IOM Study That Shows the Path to Eradicate Hepatitis B and C - Abbott
Abbott Receives European Regulatory Approval for New Ovarian Cancer Diagnostic Test - Advaxis, Inc.
Advaxis to Present at the Sidoti Microcap 2010 Investor Conference - Aetna and US Oncology, Inc.
Study of Evidence-Based Treatment for Lung Cancer Patients Shows Enhanced Value: Equivalent Outcomes and a 35 Percent Cost Savings - More from this issue of Oncology Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
